Stephen L. Eck - Feb 8, 2024 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role
Chief Medical Officer
Signature
/s/ Lynn M. Cilinski, Attorney-in-fact
Stock symbol
MGNX
Transactions as of
Feb 8, 2024
Transactions value $
$0
Form type
4
Date filed
2/12/2024, 05:31 PM
Previous filing
Feb 17, 2023
Next filing
Feb 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee Stock Option (right to buy) Award $0 +90K $0.00 90K Feb 8, 2024 Common Stock 90K $18.30 Direct F1
transaction MGNX Restricted Stock Unit Award $0 +33.5K $0.00 33.5K Feb 8, 2024 Common Stock 33.5K $0.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.
F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.